Structural characterization and inhibitory profile of formyl peptide receptor 2 selective peptides descending from a PIP2-binding domain of gelsolin

Journal of Immunology

Volumn 189, Issue 2, 2012, Pages 629-637

  Forsman, Huamei ^a   Andréasson, Emil ^a   Karlsson, Jennie ^a   Boulay, Francois ^b,c,d,e   Rabiet, Marie Josèphe ^b,c,d,e   Dahlgren, Claes ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CEA GRENOBLE   (France)

^c INSERM   (France)

^d CNRS   (France)

^e UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BETA GALACTOSIDE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; GELSOLIN; PEPTIDE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHODAMINE B GLUTAMYLARGINYLLEUCYLPHENYLALANYLGLUTAMYLVALYLLYSLGLYCYLARGINYLARGINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; MEMBRANE PERMEABILITY; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; CELL MEMBRANE PERMEABILITY; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GELSOLIN; HL-60 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NEUTROPHIL ACTIVATION; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN;

EID: 84863631913     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101616     Document Type: Article

References (45)

1. Khansari, N., Y. Shakiba, and M. Mahmoudi. 2009. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 3: 73-80.
2. Weissmann, G. 2004. Pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 10(3, Suppl)S26-S31. (Pubitemid 38812918)
3. Liu, H., and R. M. Pope. 2004. Phagocytes: mechanisms of inflammation and tissue destruction. Rheum. Dis. Clin. North Am. 30: 19-39, v. (Pubitemid 38234767)
4. Seki, H., T. Sasaki, T. Ueda, and M. Arita. 2010. Resolvins as regulators of the immune system. ScientificWorldJournal 10: 818-831.
5. Perretti, M., and F. D'Acquisto. 2006. Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Inflamm. Allergy Drug Targets 5: 107-114. (Pubitemid 43796672)
6. Hersberger, M. 2010. Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins. Clin. Chem. Lab. Med. 48: 1063-1073.
7. Perretti, M., and J. Dalli. 2009. Exploiting the annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br. J. Pharmacol. 158: 936-946.
8. Chiang, N., C. N. Serhan, S. E. Dahlén, J. M. Drazen, D. W. Hay, G. E. Rovati, T. Shimizu, T. Yokomizo, and C. Brink. 2006. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58: 463-487. (Pubitemid 44394909)
9. Ye, R. D., F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy. 2009. International Union of Basic and Clinical Pharmacology, LXXII: Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119-161.
10. Zhang, Q., M. Raoof, Y. Chen, Y. Sumi, T. Sursal, W. Junger, K. Brohi, K. Itagaki, and C. J. Hauser. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107.
11. Forsman, H., K. Christenson, J. Bylund, and C. Dahlgren. 2012. Receptor-dependent and -independent immunomodulatory effects of phenol-soluble modulin peptides from Staphylococcus aureus on human neutrophils are abrogated through peptide inactivation by reactive oxygen species. Infect. Immun. 80: 1987-1985.
12. Kretschmer, D., A. K. Gleske, M. Rautenberg, R. Wang, M. Köberle, E. Bohn, T. Schöneberg, M. J. Rabiet, F. Boulay, S. J. Klebanoff, et al. 2010. Human formyl peptide receptor 2 senses highly pathogenic Staphylococcus aureus. Cell Host Microbe 7: 463-473.
13. Chen, K., Y. Le, Y. Liu, W. Gong, G. Ying, J. Huang, T. Yoshimura, L. Tessarollo, and J. M. Wang. 2010. A critical role for the G protein-coupled receptor mFPR2 in airway inflammation and immune responses. J. Immunol. 184: 3331-3335.
14. Dufton, N., R. Hannon, V. Brancaleone, J. Dalli, H. B. Patel, M. Gray, F. D'Acquisto, J. C. Buckingham, M. Perretti, and R. J. Flower. 2010. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184: 2611-2619.
15. Cunningham, C. C., R. Vegners, R. Bucki, M. Funaki, N. Korde, J. H. Hartwig, T. P. Stossel, and P. A. Janmey. 2001. Cell permeant polyphosphoinositide-binding peptides that block cell motility and actin assembly. J. Biol. Chem. 276: 43390-43399.
16. Fu, H., L. Björkman, P. Janmey, A. Karlsson, J. Karlsson, C. Movitz, and C. Dahlgren. 2004. The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide. BMC Cell Biol. 5: 50.
17. Forsman, H., and C. Dahlgren. 2010. The FPR2-induced rise in cytosolic calcium in human neutrophils relies on an emptying of intracellular calcium stores and is inhibited by a gelsolin-derived PIP2-binding peptide. BMC Cell Biol. 11: 52.
18. Bøyum, A., D. Løvhaug, L. Tresland, and E. M. Nordlie. 1991. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34: 697-712.
19. 4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276: 21585-21593.
20. Dahlgren, C., T. Christophe, F. Boulay, P. N. Madianos, M. J. Rabiet, and A. Karlsson. 2000. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A4 receptor. Blood 95: 1810-1818. (Pubitemid 30120847)
21. Zhen, L., A. A. King, Y. Xiao, S. J. Chanock, S. H. Orkin, and M. C. Dinauer. 1993. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc. Natl. Acad. Sci. USA 90: 9832-9836. (Pubitemid 23328204)
22. Yon, J., and M. Fried. 1989. Precise gene fusion by PCR. Nucleic Acids Res. 17: 4895. (Pubitemid 19165069)
23. Dahlgren, C., and A. Karlsson. 1999. Respiratory burst in human neutrophils. J. Immunol. Methods 232: 3-14. (Pubitemid 30017761)
24. Dahlgren, C., A. Karlsson, and J. Bylund. 2007. Measurement of respiratory burst products generated by professional phagocytes. Methods Mol. Biol. 412: 349-363.
25. Bellner, L., J. Karlsson, H. Fu, F. Boulay, C. Dahlgren, K. Eriksson, and A. Karlsson. 2007. A monocyte-specific peptide from herpes simplex virus type 2 glycoprotein G activates the NADPH-oxidase but not chemotaxis through a G-protein-coupled receptor distinct from the members of the formyl peptide receptor family. J. Immunol. 179: 6080-6087.
26. Bucki, R., P. A. Janmey, R. Vegners, F. Giraud, and J. C. Sulpice. 2001. Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide. Biochemistry 40: 15752-15761. (Pubitemid 34015204)
27. Bucki, R., J. J. Pastore, P. Randhawa, R. Vegners, D. J. Weiner, and P. A. Janmey. 2004. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob. Agents Chemother. 48: 1526-1533. (Pubitemid 38544355)
28. 2+ influx across the plasma membrane of human neutrophils. Mol. Pharmacol. 30: 437-443.
29. Krishnamoorthy, S., A. Recchiuti, N. Chiang, S. Yacoubian, C. H. Lee, R. Yang, N. A. Petasis, and C. N. Serhan. 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107: 1660-1665.
30. Olson, K. R., and R. M. Eglen. 2007. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev. Technol. 5: 137-144. (Pubitemid 46581247)
31. Lee, H. Y., S. D. Kim, J. W. Shim, H. J. Kim, J. Y. Kwon, J. M. Kim, S. H. Baek, J. S. Park, and Y. S. Bae. 2010. Activation of human monocytes by a formyl peptide receptor 2-derived pepducin. FEBS Lett. 584: 4102-4108.
32. 12 is a core structure for interaction with the formyl peptide receptor 1. J. Biol. Chem. 285: 14338-14345.
33. Kirpotina, L. N., A. I. Khlebnikov, I. A. Schepetkin, R. D. Ye, M. J. Rabiet, M. A. Jutila, and M. T. Quinn. 2010. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol. Pharmacol. 77: 159-170.
34. Covic, L., A. L. Gresser, J. Talavera, S. Swift, and A. Kuliopulos. 2002. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA 99: 643-648. (Pubitemid 34106565)
35. O'Callaghan, K., A. Kuliopulos, and L. Covic. 2012. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J. Biol. Chem. 287: 12787-12796.
36. Fu, H., J. Karlsson, J. Bylund, C. Movitz, A. Karlsson, and C. Dahlgren. 2006. Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leukoc. Biol. 79: 247-256. (Pubitemid 44831156)
37. Gehret, A. U., and P. M. Hinkle. 2010. Importance of regions outside the cytoplasmic tail of G-protein-coupled receptors for phosphorylation and dephosphorylation. Biochem. J. 428: 235-245.
38. Schreiber, R. E., E. R. Prossnitz, R. D. Ye, C. G. Cochrane, and G. M. Bokoch. 1994. Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling: mapping with receptor-derived peptides. J. Biol. Chem. 269: 326-331.
39. Tressel, S. L., G. Koukos, B. Tchernychev, S. L. Jacques, L. Covic, and A. Kuliopulos. 2011. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol. Biol. 683: 259-275.
40. 4? Scand. J. Immunol. 74: 227-234.
41. Yang, K. H., H. Fang, J. S. Ye, J. Z. Gong, J. T. Wang, and W. F. Xu. 2008. The main functions and structural modifications of tripeptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) as a chemotactic factor. Pharmazie 63: 779-783.
42. Southgate, E. L., R. L. He, J. L. Gao, P. M. Murphy, M. Nanamori, and R. D. Ye. 2008. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J. Immunol. 181: 1429-1437.
43. Rabiet, M. J., E. Huet, and F. Boulay. 2005. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 35: 2486-2495. (Pubitemid 41179770)
44. Christophe, T., A. Karlsson, M. J. Rabiet, F. Boulay, and C. Dahlgren. 2002. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand. J. Immunol. 56: 470-476. (Pubitemid 35373683)
45. 4 metabolites/analogues from two commercial sources have no effects on TNF-α-mediated priming or activation through the neutrophil formyl peptide receptors. Scand. J. Immunol. 70: 396-402.